Other ovarian cancer-associated antigens as potential therapeutic vaccine targets include human epidermal growth factor receptor 2 (HER-2/neu), MUC1, Ca-125, FR-a, p53-synthetic long peptide, Wilms’ tumour 1 (WT1) peptide, and New-York-oesophageal squamous cell carcinoma-1 (NY-ESO-1)[173]. This evidence concerns the gene MUC16 and ovarian carcinoma.